Stable Transfection and Overexpression of Metallothionein Isoform 3 Inhibits the Growth of MCF-7 and Hs578T Cells but not that of T-47D or MDA-MB-231 Cells

[1]  I. O. Ellis,et al.  Presence and possible significance of immunocytochemically demonstrable metallothionein over-expression in primary invasive ductal carcinoma of the breast , 2005, Virchows Archiv A.

[2]  M. Nadji,et al.  Localization of metallothionein in breast carcinomas. An immunohistochemical study , 2005, Virchows Archiv.

[3]  M. Tötsch,et al.  Immunohistochemical demonstration of metallothionein in normal human breast tissue and benign and malignant breast lesions , 2004, Breast Cancer Research and Treatment.

[4]  S. Garrett,et al.  Metallothionein isoform 3 expression inhibits cell growth and increases drug resistance of PC‐3 prostate cancer cells , 2002, The Prostate.

[5]  H. Jörnvall,et al.  Brain-specific metallothionein-3 has higher metal-binding capacity than ubiquitous metallothioneins and binds metals noncooperatively. , 2002, Biochemistry.

[6]  G. Öz,et al.  Three-dimensional structure and dynamics of a brain specific growth inhibitory factor: metallothionein-3. , 2001, Biochemistry.

[7]  M. Duffy,et al.  Biochemical markers in breast cancer: which ones are clinically useful? , 2001, Clinical biochemistry.

[8]  S. Garrett,et al.  Metallothionein isoform 3 overexpression is associated with breast cancers having a poor prognosis. , 2001, The American journal of pathology.

[9]  D. Winge,et al.  Effect of the two conserved prolines of human growth inhibitory factor (metallothionein-3) on its biological activity and structure fluctuation: comparison with a mutant protein. , 2000, Biochemistry.

[10]  S. Garrett,et al.  Metallothionein isoform 1 and 2 gene expression in the human prostate: Downregulation of MT‐1X in advanced prostate cancer , 2000, The Prostate.

[11]  D. Lamm,et al.  Metallothionein isoform 3 as a potential biomarker for human bladder cancer. , 2000, Environmental health perspectives.

[12]  S. Garrett,et al.  Metallothionein isoform 3 expression in the human prostate and cancer‐derived cell lines , 1999, The Prostate.

[13]  D. Winge,et al.  Evidence for a dynamic structure of human neuronal growth inhibitory factor and for major rearrangements of its metal-thiolate clusters. , 1999, Biochemistry.

[14]  E. Ioachim,et al.  Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation. , 1999, Anticancer research.

[15]  S. Garrett,et al.  Expression of MT-3 protein in the human kidney. , 1999, Toxicology letters.

[16]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[17]  S. Garrett,et al.  Differential expression of the MT-1E gene in estrogen-receptor-positive and -negative human breast cancer cell lines. , 1998, The American journal of pathology.

[18]  R. Palmiter,et al.  Metallothioneins in brain--the role in physiology and pathology. , 1997, Toxicology and applied pharmacology.

[19]  T. Nakajima,et al.  Immunohistochemical expression of metallothionein in invasive breast cancer in relation to proliferative activity, histology and prognosis. , 1996, Oncology.

[20]  H. Goulding,et al.  Metallothionein expression in human breast cancer. , 1995, British Journal of Cancer.

[21]  P. Pauwels,et al.  Modulation of metallothionein-III mRNA content and growth rate of rat C6-glial cells by transfection with human 5-HT1D receptor genes. , 1995, Biochemical and biophysical research communications.

[22]  R. Palmiter,et al.  Bioactivity of metallothionein-3 correlates with its novel beta domain sequence rather than metal binding properties. , 1995, Biochemistry.

[23]  K. Horgan,et al.  Metallothionein expression in duct carcinoma in situ of the breast. , 1995, Human pathology.

[24]  F. Stennard,et al.  Characterisation of six additional human metallothionein genes. , 1994, Biochimica et biophysica acta.

[25]  K. Zedeler,et al.  Immunohistochemical detection of metallothionein in primary breast carcinomas and their axillary lymph node metastases. , 1994, Pathology, research and practice.

[26]  R. Palmiter,et al.  Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified squamous epithelia. , 1994, Biochemistry.

[27]  R. Palmiter,et al.  MT-III, a brain-specific member of the metallothionein gene family. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[28]  S. Tsuji,et al.  Molecular cloning of human growth inhibitory factor cDNA and its down‐regulation in Alzheimer's disease. , 1992, The EMBO journal.

[29]  K. Titani,et al.  The growth inhibitory factor that is deficient in the Alzheimer's disease brain is a 68 amino acid metallothionein-like protein , 1991, Neuron.

[30]  C. E. Hildebrand,et al.  Human metallothionein genes: structure of the functional locus at 16q13. , 1990, Genomics.

[31]  W. McGuire,et al.  The value of estrogen and progesterone receptors in the treatment of breast cancer , 1980, Cancer.